The efficacy and safety of a newly developed
miconazole preparation (MJR-1761) for
intravenous drip infusion were evaluated in 22 patients with
hematological diseases complicated by documented or suspected deep-seated
fungal infections. They consisted of 15 patients with
fungemia, 2 patients with pulmonary mycosis, and 5 patients with mycosis of the digestive tract. Of the 5 patients, 3 had a complication of
fungemia and 1 a complication of urinary tract mycosis. Of the 22 patients, 21 were clinically evaluable. All the patients were included in safety evaluation. The effective rate was 86% (18/21) when moderately improved or better evaluations were included, and the usefulness rate was 81% (17/21) when moderately or more useful evaluations were taken into consideration. Side effects occurred in 4 patients, and abnormal laboratory values were obtained in 4 patients. All these changes, which were previously reported, improved after the discontinuation of the treatment. The results presented indicate that the
miconazole intravenous drip infusion
solution used in this study is as effective as conventional similar preparations. Since the infusion
solution need not be diluted immediately before use, it is simple to use, and its safety may be highly rated. The purpose can be met with less volume of
solution per use than before because the preparation contains as much as 200 mg of
miconazole in 75 ml of
solution. This preparation seems to lend itself better to clinical application than conventional similar infusion solutions.